This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Genotropin® is a GH therapy indicated for GHD1
The dosage and administration schedule should be individualised. The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
Growth disturbance due to insufficient secretion of GH in children
Generally, a dose of 0.025 to 0.035 mg/kg body weight per day (0.7-1.0 mg/m² body surface area per day) is recommended. Even higher doses have been used. Where childhood-onset GHD persists into adolescence, treatment should be continued to achieve full somatic development
(e.g. body composition and bone mass). For monitoring, the attainment of a normal peak bone mass defined as a T score >−1 (i.e. standardised to average adult peak bone mass measured by dual energy X-ray absorptiometry taking into account sex and ethnicity) is one of the therapeutic objectives during the transition period.
PWS for the improvement of growth and body composition in children
Growth disturbance due to TS
A dose of 0.045 to 0.050 mg/kg body weight per day (1.4 mg/m² body surface area per day) is recommended.
Growth disturbance in short children born SGA
A dose of 0.035 mg/kg body weight per day (1 mg/m² body surface area per day) is usually recommended until the final height is reached (see Section 5.1). Treatment should be discontinued after the first year of treatment if the height velocity SDS is below +1. Treatment should be discontinued if the height velocity is <2 cm/year and, if confirmation is required, bone age is >14 years (girls) or >16 years (boys), corresponding to the closure of the epiphyseal growth plates.
Dosage Recommendations in Pediatric Patients
Adapted from Genotropin. Local product document. 2022. LPDSOM052020.
GH, growth hormone; GHD, growth hormone deficiency; PWS, Prader-Willi syndrome; SDS, standard deviation score; SGA, small for gestational age; TS, Turner syndrome.
Reference:
Indication |
mg/kg body weight dose per day |
mg/m2 body surface area dose per day |
---|---|---|
Growth hormone deficiency in children |
0.025 - 0.035 | 0.7 - 1.0 |
Prader-Willi syndrome in children |
0.035 | 1.0 |
Turner syndrome | 0.045 - 0.050 | 1.4 |
Chronic renal insuffciency | 0.045 - 0.050 | 1.4 |
Children born small for gestational age |
0.035 | 1.0 |
PP-GEN-IND-0678 July 2022
Simplicity and flexibility in administration1
Multiple support materials
Review the upcoming events
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.